VIENNA—At the St Gallen Breast Cancer Conference BCL-2 was named as a therapeutic target for patients with hormone-receptor positive breast cancer by Geoffrey J Lindeman BSc(Med) PhD, from the University of Melbourne and the Walter and Eliza Hall Institute of Medical Research and head of the Familial Cancer Centre at The Royal Melbourne Hospital, Australia. He discussed the clinical potential of BCL-2 modulation with Oncology Times reporter Sarah Maxwell.
You may also like...
Which Tasks Most Influence Pediatric PT Productivity, Effectiveness? 31 Dec, 2019 Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes 26 Mar, 2015 Patients with oropharyngeal cancer: no HPV risk to spouses, partners 21 Jun, 2013 Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib 15 Oct, 2018
- Previous story Tumor Microenvironment: Tumor Infiltrating Lymphocyte Score Predicts Breast Cancer Outcome
- Next story Targeting Bone Microenvironment in Breast Cancer
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014